Dupuytren's disease: a localised and accessible human fibrotic disorder

Dupuytren's disease: a localised and accessible human fibrotic disorder

We review the biology of Dupuytren's disease (DD), a common localised fibrotic disorder of the hand. The disease develops through a complex interplay of genetic and environmental factors, and epigenetic signalling. The early-stage disease nodules comprise a complex milieu of stromal and immune...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Layton, TB, Williams, L, Nanchahal, J
Format:	Journal article
Język:	English
Wydane:	Cell Press 2022

Podobne zapisy

Single cell analysis of the fibrotic landscape in Dupuytren's disease
od: Layton, T
Wydane: (2019)

Recent advances in the understanding of Dupuytren's disease
od: Nanchahal, J, i wsp.
Wydane: (2019)

Treatment for Dupuytren's disease
od: Nanchahal, J, i wsp.
Wydane: (2013)

A vasculature niche orchestrates stromal cell phenotype through PDGF signaling: importance in human fibrotic disease
od: Layton, TB, i wsp.
Wydane: (2022)

Tonometry as an outcome measure for the treatment of Dupuytren’s disease.
od: Ball, C, i wsp.
Wydane: (2015)

Tonometry as an outcome measure for the treatment of Dupuytren’s disease.
od: Ball, C, i wsp.
Wydane: (2016)

Treatments for early-stage Dupuytren’s disease: an evidence-based approach
od: Nanchahal, J, i wsp.
Wydane: (2023)

A systematic review of non-surgical treatments for early Dupuytren’s disease
od: Ball, C, i wsp.
Wydane: (2015)

Verteporfin ameliorates fibrotic aspects of Dupuytren’s disease nodular fibroblasts irrespective the activation state of the cells
od: Nataly Puerta Cavanzo, i wsp.
Wydane: (2022-08-01)

Systematic review of non-surgical treatments for early Dupuytren’s disease
od: Ball, C, i wsp.
Wydane: (2016)

Predicting the outcome of surgery for the proximal interphalangeal joint in Dupuytren's disease.
od: Misra, A, i wsp.
Wydane: (2007)

Dupuytren’s disease
od: Richard Trèves
Wydane: (2011-09-01)

Dupuytren's disease
od: Rames Mattar Junior
Wydane: (2008-03-01)

Myofibroblast distribution in Dupuytren's cords: correlation with digital contracture.
od: Verjee, L, i wsp.
Wydane: (2009)

What do we know about managing Dupuytren’s Disease cost-effectively?
od: Dritsaki, M, i wsp.
Wydane: (2018)

Optimal functional outcome measures for assessing treatment for Dupuytren's disease: a systematic review and recommendations for future practice.
od: Ball, C, i wsp.
Wydane: (2013)

Method of treating a localized fibrotic disorder using an IL-33 antagonist
od: Jagdeep Nanchahal, i wsp.
Wydane: (2018)

What do we know about managing Dupuytren’s disease cost-effectively?
od: Melina Dritsaki, i wsp.
Wydane: (2018-01-01)

Economic evaluation plan of a randomised controlled trial of intra-nodular injection of anti-TNF and placebo among patients with early Dupuytren’s disease: Repurposing Anti-TNF for Treating Dupuytren’s Disease (RIDD)
od: Png, M, i wsp.
Wydane: (2019)

Paediatric Dupuytren's disease
od: Pradeoth Mukundan Korambayil, i wsp.
Wydane: (2011-09-01)

Isometric contraction of Dupuytren's myofibroblasts is inhibited by blocking intercellular junctions.
od: Verhoekx, J, i wsp.
Wydane: (2013)

Isometric contraction of dupuytren's myofibroblasts is inhibited by blocking intercellular junctions
od: Verhoekx, J, i wsp.
Wydane: (2013)

A genome-wide association meta-analysis implicates Hedgehog and Notch signaling in Dupuytren’s disease
od: Sophie A. Riesmeijer, i wsp.
Wydane: (2024-01-01)

Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target.
od: Verjee, L, i wsp.
Wydane: (2013)

Unravelling the signalling pathways promoting fibrosis in dupuytren's disease reveals TNF as a therapeutic target
od: Verjee, L, i wsp.
Wydane: (2014)

Collagen VI as a driver and disease biomarker in human fibrosis
od: Williams, L, i wsp.
Wydane: (2021)

Wnt signaling and Dupuytren's disease.
od: Dolmans, G, i wsp.
Wydane: (2011)

The molecular genetics of dupuytren disease
od: Ng, M
Wydane: (2018)

Post-transcriptional regulation of alpha-smooth muscle actin determines the contractile phenotype of Dupuytren's nodular cells.
od: Verjee, L, i wsp.
Wydane: (2010)

Economic evaluation plan of a randomised controlled trial of intra-nodular injection of anti-TNF and placebo among patients with early Dupuytren’s disease: Repurposing Anti-TNF for Treating Dupuytren’s Disease (RIDD) [version 2; referees: 2 approved]
od: May Ee Png, i wsp.
Wydane: (2019-02-01)

Is Dupuytren’s disease really a “disease of the Vikings”?
od: Ng, M, i wsp.
Wydane: (2019)

Guillaume Dupuytren
od: Romina A Parquet
Wydane: (2013-01-01)

Sibling recurrence risk in Dupuytren's disease.
od: Capstick, R, i wsp.
Wydane: (2013)

Dupuytrens disease–where to from here?
od: David B McCombe
Wydane: (2019-03-01)

Epidemiological analysis of patients with Dupuytren's disease
od: Henrique Gonçalves Mansur, i wsp.

Surgical treatment results for dupuytren's disease
od: Serkan Aykut, i wsp.
Wydane: (2017-06-01)

The Rationale for Treating the Nodule in Dupuytren’s Disease
od: Lynn D. Ketchum, MD
Wydane: (2014-12-01)

Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300
od: Williams, LM, i wsp.
Wydane: (2020)

Enfermedad de Dupuytren
od: J. M. Arandes Renú
Wydane: (2010-11-01)

Genome-wide analysis using exon arrays demonstrates an important role for expression of extra-cellular matrix, fibrotic control and tissue remodelling genes in Dupuytren's disease.
od: Helen B Forrester, i wsp.
Wydane: (2013-01-01)